🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — October 23, 2026

The IPO Pipeline stream for 2026-10-23 contains three SEC filings, and the enriched data supplied is thin: none of the three excerpts contains narrative financial figures, period-over-period comparisons, insider transactions, capital allocation detail, or forward-looking guidance that could support quantitative trend analysis. The dominant themes are SPAC-related and resale-driven capital markets activity rather than fresh IPO issuance. Alchemy Acquisition Holdings (ALCY) is a distressed SPAC that missed its 36-month business combination deadline, was suspended from Nasdaq on May 14, 2026, and trades on OTC Pink with no third-party valuation or fairness opinion supporting its pending Cartiga merger. Evernorth's S-1 is a registration whose embedded XBRL metadata relates to Armada Acquisition Corp. II, with XRP-linked subscription agreements, but the excerpt contains no verifiable dollar amounts. Onfolio (ONFO) is registering resale of up to 105.2 million shares under an equity line capped at $100 million, at a sub-$1 price, which signals meaningful dilution pressure. Because the underlying figures cannot be verified from the supplied content, conclusions below are directional and should be confirmed against the full filings before any position is taken.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — October 23, 2026

All nine filings in this USA Trading Suspensions stream are Nasdaq or NYSE listing-compliance notices, not trading suspensions, delistings actually executed, or regulatory halts; they are best read as a cluster of distressed micro- and small-cap issuers approaching or past exchange cure deadlines. The dominant theme is stockholders' equity and minimum bid price deficiencies: Lunai Bioworks is voluntarily delisting with suspension expected October 30, 2026, Dragonfly Energy has until December 31, 2026 to evidence equity compliance, and Polar Power claims it has regained compliance using insider-driven conversions and dilutive financings. Bid-price deficiencies cluster around April 19-21, 2027 deadlines for Akebia, Laser Photonics, Century Casinos (MVLS), and Innventure, while Medicus Pharma cured its bid price on October 23, 2026 after a delisting determination. Enriched period-over-period comparison fields were not populated in the provided summaries, so quantitative trend claims are limited to balance-sheet snapshots (e.g., Lunai deficit of $(9.02)M, Dragonfly deficit of $(184)K) rather than YoY/QoQ growth or margin trends. Portfolio-level implication: near-term event risk is concentrated in Lunai's October 30 suspension and Polar's October 28 compliance-evidencing filing, with the rest a slower-burning 2026-2027 delisting pipeline.

9 high priority 9 total filings
· daily

US Executive Officer Management Changes SEC — October 23, 2026

The 39 filings in this Officer and Director Change stream (all dated 2026-10-23 window) are dominated by governance housekeeping: routine director resignations, interim CFO and CAO appointments, and succession moves, most explicitly stated as not involving any disagreement with the company. The material exceptions are Lumen's Q3 2026 preliminary results and CEO appointment (LKQ, materiality 9/10) that withdrew full-year guidance and show a 5.4% parts and services organic decline with Europe down 9.8%, and Ardent Health's recharacterization of former CEO Bonick's separation as a for-Cause termination with about $4.5M of severance discontinued and PRSUs cancelled. Finance-function turnover is elevated, with CFO or principal accounting officer changes at Premier Air Charter, Offerpad, Methode Electronics and AB Commercial Real Estate Debt Fund, and two more executive exits (Acadia's head of R&D and Andersons' CHRO). Capital-related dilution and restructuring appear in Bio Essence, Tessera/BiomX and Reliance Global, while compensation is trending upward at Edesa Biotech (base salaries up roughly 75-84% retroactive to July 2026) and Freshpet. Governance is being refreshed through several independent-director additions (Vivid Seats, Fiserv, Civista, FS Bancorp) and multiple planned retirements in 2026-2027. Overall the market implication is limited for most names, with LKQ and Ardent the main items needing active attention.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 23, 2026

The 39 filings for the 'USA Board Room Changes' stream (all dated 2026-10-23 window) are overwhelmingly governance-focused: officer and director departures, interim appointments, severance and retention arrangements, and board refreshes. The most material event is LQR-style-free but clearly consequential: LKQ Corporation's preliminary Q3 2026 results (revenue $3.32B vs $3.50B, net loss of $16M-$32M including $111M impairments, adjusted EPS $0.47-$0.53 vs $0.84, Europe margin compressing to 4.1%-5.1% from 10.0%) combined with a CEO change to Salvatore Abbate effective December 15, 2026 and withdrawn full-year guidance. Insider and compensation signals are mixed: Ardent Health is recharacterizing a former CEO's exit as 'for Cause' and cancelling ~$4.5M of severance and PRSUs, while Edesa Biotech roughly doubled executive base salaries (+75% to +84%) retroactively. Several CFO and CAO transitions (Offerpad, Methode, Premier Air, AB Commercial Real Estate Fund) cluster around interim arrangements, a pattern that raises near-term reporting-continuity questions. Filings lacking quantitative financial data (most governance-only 8-Ks) were scored on governance significance rather than performance trends, so period-over-period comparisons are available for only a handful of companies.

39 high priority 39 total filings
· daily

USA Insider Trading Pulse — October 23, 2026

Across the 50 SEC Section 16 / Form 4 filings dated 2026-10-23, insider activity is dominated by routine equity compensation (RSU, phantom stock, and Class F/T unit awards to directors and officers), which carries little directional signal. The meaningful signal sits in a smaller set of open-market trades: a cluster of notable sales by Travelers Companies executives (including a $13.2M sale by EVP Gregory Toczydlowski at $403.86 and a $3.66M sale by Jeffrey Klenk, both paired with option exercises), a $13.9M sale by 10% owner IGNITE AGGREGATOR LP in InnovAge, and a $3.55 private placement-style purchase cluster in Rent the Runway by Nexus Capital and CHS US Investments. Insider buying is concentrated in small-cap and fund names (AIM ImmunoTech, Cascade Real Assets, Vista Credit, Baozun, Waste Energy), while selling is concentrated in large-cap names with 10b5-1 plan disclosure. Several sales were executed under Rule 10b5-1 plans, which reduces their informational value as discretionary conviction signals. Note: the supplied enriched fields for period-over-period comparisons, forward-looking guidance, and capital allocation were not populated in the input, so trend analysis here is limited to transaction-level data and no guidance or margin claims are made.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 23, 2026

Across the 15 filings dated 2026-10-23, the dominant theme is SPAC lifecycle stress and resolution: multiple blank-check vehicles are burning through extension rights (International Media at its 23rd of 24 extensions, Black Hawk, Ribbon), funding deadline extensions with trust deposits, and facing Nasdaq warrant deficiency notices (ARC Group). Against that backdrop, two near-term deal closings stand out: Melar/Everli (shareholders approved all eight proposals with 3,852,564 Class A shares redeemed, leaving roughly $0.8M in trust) and Unusual Machines' completed DroneNX/Upgrade Energy acquisition, while Blue Acquisition's Blockfusion vote is set for November 17, 2026. The most material operating-company event is 1-800-Flowers' $45.0M divestiture of its Personalization Businesses to PlanetArt, which removes roughly 9.7% of FY2026 net revenues and cuts pro forma long-term debt from $112.2M to $91.0M, a deleveraging move rather than an earnings driver. The most dilutive transaction is Bolt Biotherapeutics' reverse merger with Prana Therapies, where pre-deal Bolt holders will own only about 6.9% of common stock versus 51.7% for Prana holders and 41.4% for placement investors. Portfolio-level data is thin: most filings disclose no purchase prices, insider activity, or forward guidance, so period-over-period comparisons are available only for 1-800-Flowers and limited pro forma balance sheet data.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 23, 2026

The overnight SEC stream for 2026-10-22 to 2026-10-23 is dominated by routine Form 4 director and officer equity awards and tax withholdings across Rivian, Lyft, CoreWeave and Fervo, which carry little market signal individually. The substantive developments are concentrated in a few areas: financial-sector results with mixed profiles (Flagstar's Q3 net income collapsed to $12M with provisions up $58M QoQ, while Primis posted higher Q3 earnings but missed its 1.00% ROAA target), a large acquisition-driven growth profile at Omnicom (Q3 revenue +59.1% YoY, but nine-month operating cash flow of only $37.8M against $3.2B of buybacks), and a distressed microcap cohort (Lunai Bioworks voluntary delisting after a $(9.0)M stockholders' deficit, Boxlight's S-1 registering 47.5M resale shares against 844,556 outstanding). SPAC activity is heavy, including the Quantum Space/Inflection Point S-4/A and 425 amendments, UY Scuti's trust-extension notes, and K&F Growth's extension proxy. Biotech/pharma news centered on Zymeworks' $55M-upfront Roche license for ZW209 and Zai Lab's mixed ESMO zoci data, with KT Corp disclosing a USD 386M counterclaim equal to about 2.63% of equity. Most remaining filings are cover-page or incorporation-by-reference documents whose substantive exhibits were not provided, so their materiality cannot be verified.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — October 22, 2026

This period contains 5 FDA approvals on 2026-10-16 and 2026-10-19, all classified as FALLBACK approval types and all carrying a biosimilar label in the source analyses: 0 NMEs, 5 biosimilar-labeled approvals, and 0 label expansions. All five signals are rated neutral (5/10 strength, 5/10 materiality), with no bullish or bearish designations. Therapeutic area clustering is limited: the set spans anticoagulation (apixaban), hormonal therapy (progesterone), anticholinergic (atropine sulfate), antihistamine (loratadine), and oncology (cabozantinib S-malate), so no single therapeutic-area theme dominates. The highest-conviction item is cabozantinib S-malate from Cipla, given oncology exposure, but the source data provides no commercial metrics to support a conviction-weighted call. The principal watch item is the classification ambiguity itself: the 'biosimilar' label is applied to small-molecule generics (apixaban, cabozantinib, loratadine, atropine, progesterone), which would ordinarily be approved via ANDA rather than BLA pathways, so the regulatory pathway and originator-erosion implications should be verified before any position is taken.

5 total filings
· daily

Big Pharma Approvals — October 22, 2026

This digest covers a single approval in the Big Pharma stream for the period October 22, 2026, which means the mix is 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other (a fallback-type approval). The lone event is GlaxoSmithKline's DOSTARLIMAB-GXLY (JEMPERLI), a bullish signal rated 5/10 for both strength and materiality. No therapeutic area clustering can be established from a single approval, so no sector-wide theme is asserted. The highest-conviction signal is the reaffirmation of GSK's JEMPERLI franchise, though commercial implications cannot be quantified from the data provided. Key watch item: the source data does not disclose the indication, exclusivity, pricing, or market position, so the investment case rests on incomplete information and should be verified against primary FDA and company disclosures before any position change.

1 total filings
· daily

Orphan Drug Approvals — October 22, 2026

This period contains a single FDA action: a label expansion approval for AVAPRITINIB (AYVAKIT) from Blueprint Medicines, dated October 16, 2026, classified as a fallback approval type with bullish signal (strength 5/10, materiality 5/10). The approval mix is 0 NMEs, 0 biosimilars, 0 label expansions counted under the standard mix field, and 1 other, so no new molecular entity or biosimilar entry occurred in the window. No therapeutic area clustering can be established from a single approval, and peak sales, exclusivity, pricing power, and market position are all NOT_DISCLOSED in the source analysis. The highest-conviction signal is the bullish Blueprint Medicines AYVAKIT action, but its commercial implication is modest at the stated materiality of 5/10 and cannot be quantified from the available data. The key watch item is the absence of disclosed indication size, commercial trajectory, and next catalyst, which limits the investment read-through to a directional rather than sized conclusion.

1 total filings
· daily

New Drug Approvals (Original) — October 22, 2026

This digest covers a single-day window (October 22, 2026) containing five FDA approvals, all classified as FALLBACK approvals and all reported by the source feed as biosimilar approvals, though the feed records no NMEs, no label expansions, and five 'Other' entries. The mix is 0 NME, 0 biosimilar (as classified in the structured fields), 0 label expansion, and 5 other, with all five signals rated neutral (strength 5/10, materiality 5/10). Therapeutic coverage spans an anticoagulant (apixaban, TEVA), a hormone (progesterone, NOVAST LABS), an anticholinergic (atropine sulfate, SENTISS PHARMA), an antihistamine (loratadine, DR REDDYS), and a kinase inhibitor (cabozantinib S-malate, CIPLA), so no single therapeutic area dominates. No highest-conviction commercial signal can be established because peak sales, exclusivity, pricing power, and market position are all NOT_DISCLOSED for every entry. The key watch item is the internal inconsistency between the 'biosimilar' label in the summaries and the 'FALLBACK' approval type, which should be verified against FDA Orange Book/Purple Book records before any position is taken.

5 total filings
· daily

Federal Construction & Infrastructure Contracts — October 22, 2026

This digest covers two federal construction awards totaling $62,098,020 in obligations, both to civilian agencies with zero defense-related awards. The dominant theme is facilities construction: USDA APHIS awarded Dean Snyder Construction Co. $32,885,020 for an Animal and Zoonotic Disease Center in Ames, Iowa, and the Smithsonian Institution awarded Grunley Construction Co., Inc. $29,213,000 for sanitary and storm system upgrades at the National Museum of Natural History in Washington, DC. Both awards are firm fixed price under full and open competition, with no set-asides and no identified publicly traded parent, so direct public-market exposure is not established by the data. The highest-conviction signal is the durability of the USDA award, which runs through 2027-11-24 and has $4,718,688 (about 14.4%) outlayed. The key watch item is the Smithsonian contract, which shows $0 outlayed against a short performance window ending 2026-10-26, leaving execution and disbursement risk unresolved.

2 total filings
· daily

DOE Energy & National Labs Contracts — October 22, 2026

This digest covers a single DOE Energy & National Labs contract totaling $41,772,736 in current obligation, with zero defense-related awards in the period (the award is an NNSA delivery order, which sits within the Department of Energy rather than DOD). The dominant theme is continued federal funding for nuclear security and nonproliferation analysis through The Aerospace Corporation, a nonprofit federally funded research center. The highest-conviction signal is that the award is funded and actively disbursing, with $26,579,293 outlayed to date against a $146,156,020 base-plus-options ceiling. The primary watch item is the option exercise path and any change to the 2027-05-31 current end date or 2030-06-04 potential end date. Because the recipient is tax-exempt and not publicly traded, the contract carries no direct equity investment implication, and the signal stream is neutral.

1 total filings
· daily

DHS Homeland Security Contracts — October 22, 2026

Two DHS contracts totaling $45,156,505 in obligations were analyzed, with zero defense-related awards, so the entire digest falls on the civilian homeland security side. Universal Protection Service, LIMITED PARTNERSHIP received a $22,644,780 protective security officer delivery order from DHS/FPS (against a $401,685,093 Base + All Options ceiling) and KYC Advisors LLC received a $22,511,725 DevSecOps delivery order from USCIS (against an $82,909,800 ceiling). Both awards were rated neutral with 3/10 materiality and signal strength, and neither recipient is identified as publicly traded in the data, limiting direct equity read-through. The highest-conviction observation is that KYC's award has already moved into active performance, with $6,590,471 (about 29%) outlayed, while the Universal Protection award is pre-performance with $0 outlayed. The key watch item is option exercise on both delivery orders, since most of the potential value in each is contingent on future option exercise and funding rather than committed today.

2 total filings
· daily

VA Healthcare & Services Contracts — October 22, 2026

This digest covers a single VA Healthcare & Services award totaling $22,900,000 in total obligation, with zero defense-related records, so the entire dataset is civilian and VA-focused. The dominant theme is VA facility infrastructure spending, specifically an emergency generator upgrade awarded to CDEEM CO under a firm fixed price contract. The signal is neutral (strength 3/10, materiality 3/10): the award is a Service Disabled Veteran Owned Small Business set-aside, which reflects a policy priority rather than a pure competitive win, and no outlays have been recognized to date. The highest-conviction takeaway is that the award confirms continued VA capital spending on emergency power resilience, but the sample is too thin to infer a broader budget trend. The key watch item is whether quarterly outlays begin against the $22.9M obligation before the 2026-10-16 end date, since $0 outlayed to date creates execution uncertainty.

1 total filings
· daily

New Federal Contractors — October 22, 2026

The 13 contracts in this period total $384,742,601 in obligations, with only 1 of 13 defense-related (the CALIFORNIA INSTITUTE OF TECHNOLOGY/JPL NASA award is civilian space R&D; the defense-related award is the GUIDEHOUSE/USDA-adjacent and CQ JV/GSA PNT cybersecurity work, which is defense-adjacent, while the sole defense-coded award per the data is CQ JV, LLC's $22,928,263 military PNT and cyber support order). The dominant theme is civilian agency spending across NASA, HHS/NIH, DOE NNSA, USDA, Smithsonian, VA, DHS, DOT and GSA, with no award rising to a level that reshapes any listed-company thesis. The highest-conviction signal is the Veritas-owned GUIDEHOUSE $25,706,592 USDA Rural Housing Service call order, though its public-market relevance is limited by private-equity ownership. Every contract is classified neutral with strength 2-3/10, so the digest carries no bullish or bearish directional calls. The key watch item is the $0 outlay position on several recent awards (Grunley, GUIDEHOUSE, CDEEM, UNIVERSAL PROTECTION, CQ JV), meaning cash realization remains unproven.

13 total filings
· daily

Significant Contract Modifications ($10M+) — October 22, 2026

Thirteen significant contract modifications totaling $384,742,601 in obligations were recorded in this single-day window, but only one (The Aerospace Corporation's NNSA delivery order, $41,772,736, and the separately listed NASA/JPL award) falls in a defense-adjacent or national-security context, leaving the stream overwhelmingly civilian: roughly 12 of 13 awards come from HHS, USDA, Smithsonian, GSA, VA, DHS, and DOT. The dominant theme is professional and construction services spread across many small and mid-sized private contractors, with no single publicly traded parent identified as a material beneficiary. Every contract was classified neutral (average signal strength 2.9/10), and the highest-materiality items (Caltech/JPL GOMAP at $54.0M, WGL Energy Services at $44.5M) are either nonprofit or foreign-parented, so direct public-equity read-through is limited. The key watch item is outlay conversion: most recent awards show $0 or low disbursement (e.g., Grunley $0 of $29.2M, CQ JV $0 of $22.9M, CDEEM $0 of $22.9M, Universal Protection $0 of $22.6M), so cash realization remains unproven.

13 total filings
· daily

Contract Deobligations Alert — October 22, 2026

This digest covers 13 federal contract awards totaling $384,742,601 in obligations, of which only one (The Aerospace Corporation's DOE/NNSA delivery order, $41,772,736) is defense-related; the remaining 12 are civilian (HHS, USDA, Smithsonian, GSA, VA, DHS, DOT). The dominant theme is civilian facilities construction and professional/IT services across HHS, USDA, and DHS rather than a defense modernization wave. Every contract was rated neutral (average signal strength 2.9/10), so no contract in this set provides a high-conviction bullish or bearish signal for public equities. Most recipients are private, nonprofit, or PE-owned entities (e.g., GUIDEHOUSE/Veritas Capital, Caltech, Aerospace Corporation), limiting direct public-market exposure. The key watch item is the sizable pre-performance backlog: several awards show $0 outlayed (Grunley Construction at $29,213,000, CDEEM at $22,900,000, Universal Protection Service at $22,644,780), so revenue realization is unproven.

13 total filings
· daily

Contract Option Exercises — October 22, 2026

The 13 contract option exercises in this period total $384,742,601 in aggregate obligation, with only one defense-related award (1 of 13), so the stream is overwhelmingly civilian: NASA, HHS/NIH and CMS, USDA, DHS, GSA, VA, DOT/FAA and the Smithsonian dominate. The dominant themes are professional and IT services (USCIS DevSecOps, NIH AT3 IT support, FAA consulting) and facilities construction (USDA APHIS, Smithsonian, VA generator upgrades), with the largest single civilian awards going to non-public or subsidiary recipients such as California Institute of Technology ($54,049,346), The Aerospace Corporation ($41,772,736) and WGL Energy Services ($44,527,131). Every contract is classified neutral (average signal strength 2.9/10), so no award in this stream is a high-conviction public-equity signal. The key watch item is that most obligations show low or zero outlays (Grunley $0 of $29,213,000, CQ JV $0 of $22,928,263, CDEEM $0 of $22,900,000, Guidehouse $0 of $25,706,592), so cash realization and option exercise remain unproven across much of the value.

13 total filings
· daily

Federal Professional Services Contracts — October 22, 2026

Two federal professional services awards totaling $46,959,723 in obligations were reviewed, both civilian and neither defense-related: GUIDEHOUSE INC.'s $25,706,592 firm-fixed-price BPA Call Order from USDA Rural Housing Service (awarded 2026-09-22) and SALIENSE CONSULTING LLC's $21,253,130 time-and-materials FAA delivery order (awarded 2023-07-07, Department of Transportation). The dominant theme is civilian management and technical consulting spend, with no sector-wide trend data available to confirm growth or contraction. The highest-conviction observation is that SALIENSE has already outlayed $16,168,978, about 76% of its current obligation, which signals a funded, actively consumed engagement, though the data does not establish public-market exposure for either firm. GUIDEHOUSE's parent is a private equity fund and SALIENSE's public status is unstated, so investment relevance is limited. Key watch item: GUIDEHOUSE's $0 outlayed to date means cash realization over 2026-09-27 to 2027-09-26 is unproven, and SALIENSE's option decision around 2027-07-09 determines whether the remaining $20,020,459 of its ceiling is realized.

2 total filings